New
HealthMore in Health→
Approved Cancer Drug SAHA May Shield the Heart During Doxorubicin Chemotherapy
Key Takeaways
- Heidelberg researchers identified the molecular signaling pathway through which doxorubicin damages heart muscle, centered on topoisomerase IIβ and MEF2.
- SAHA, a drug already approved for certain cancers, attenuated harmful mechanisms in heart muscle cells in cell-based and animal studies.
- SAHA protected against chronic doxorubicin-induced cardiac dysfunction, fibrosis and transcriptional remodeling in vivo.
- Measurable changes in cardiac function appear in roughly one-quarter of doxorubicin-treated patients, raising long-term heart failure risk.
DE
DT Editorial Team··via medicalxpress.com